Identification of Endocannabinoid Predictors of Treatment Outcomes in Major Depressive Disorder: A Secondary Analysis of the First Canadian Biomarker Integration Network in Depression (CAN-BIND 1) Study
Discussion Methylation of DAGLA is a promising candidate as a marker of treatment outcomes for MDD and needs to be explored further. [...] Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyArticle in Thieme eJournals: Table of contents  |  Abstract  |  Full text (Source: Pharmacopsychiatry)
Source: Pharmacopsychiatry - July 6, 2022 Category: Psychiatry Authors: Kim, Helena K. Zai, Gwyneth M üller, Daniel J. Husain, Muhammad I. Lam, Raymond W. Frey, Benicio N. Soares, Claudio N. Parikh, Sagar V. Milev, Roumen Foster, Jane A. Turecki, Gustavo Farzan, Faranak Mulsant, Benoit H. Kennedy, Sidney H. Tripathy, Shreejo Tags: Original Paper Source Type: research

Aripiprazole Once-Monthly Versus Oral Aripiprazole for Schizophrenia in the Maintenance Phase: A Systematic Review and Network Meta-Analysis
DiscussionAlthough both AOM and OARI were efficacious in the treatment of schizophrenia during the maintenance phase, AOM was better accepted than OARI. [...] Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyArticle in Thieme eJournals: Table of contents  |  Abstract  |  Full text (Source: Pharmacopsychiatry)
Source: Pharmacopsychiatry - July 5, 2022 Category: Psychiatry Authors: Kishi, Taro Sakuma, Kenji Iwata, Nakao Tags: Original Paper Source Type: research

Effects of antipsychotics on heart rate in treatment of schizophrenia: a systematic review and meta-analysis
CONCLUSION: Many studies do not report data for cardiac outcomes, but the available evidence indicates that treatment with antipsychotics raises the risk for tachycardia. Therefore, especially patients with cardiac risk factors should be monitored closely during antipsychotic treatment.REGISTRATION: PROSPERO: CRD42014014919.PMID:35774251 | PMC:PMC9237927 | DOI:10.1177/20451253221097261 (Source: Adv Data)
Source: Adv Data - July 1, 2022 Category: Epidemiology Authors: Maximilian Huhn Thomas Arndt Johannes Schneider-Thoma Stefan Leucht Source Type: research

Effects of antipsychotics on heart rate in treatment of schizophrenia: a systematic review and meta-analysis
CONCLUSION: Many studies do not report data for cardiac outcomes, but the available evidence indicates that treatment with antipsychotics raises the risk for tachycardia. Therefore, especially patients with cardiac risk factors should be monitored closely during antipsychotic treatment.REGISTRATION: PROSPERO: CRD42014014919.PMID:35774251 | PMC:PMC9237927 | DOI:10.1177/20451253221097261 (Source: Adv Data)
Source: Adv Data - July 1, 2022 Category: Epidemiology Authors: Maximilian Huhn Thomas Arndt Johannes Schneider-Thoma Stefan Leucht Source Type: research

Probable Interaction Between Aripiprazole and Isoniazid
No abstract available (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - July 1, 2022 Category: Psychiatry Tags: Letters to the Editors – Case Reports Source Type: research

Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs
Pharmacopsychiatry DOI: 10.1055/a-1854-0185Early-onset schizophrenia (EOS) – onset before age 18 – is linked with great disease burden and disability. Decision-making for EOS pharmacological treatment may be challenging due to conflicting information from evidence and guidelines and unidentified care needs may remain unmet.We searched for systematic reviews, meta-analyses and umbrella reviews of EOS pharmacological treatment published in PubMed over the past 10 years and selected five clinical guidelines from Europe, North-America and Australia. Based on prede...
Source: Pharmacopsychiatry - July 1, 2022 Category: Psychiatry Authors: Lopez-Morinigo, Javier-David Leucht, Stefan Arango, Celso Tags: Review Source Type: research

CO58 Long-Term Health Outcomes in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil for 1 Year
The objective of this prespecified analysis was to assess health outcomes using the EuroQol Group Health Outcome Measure-five level (EQ-5D-5L) in patients who remained on AL for up to 1 year. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: SM Gasper, S Dingman, M Wang, BD Roy Source Type: research

CO122 Patient Versus Caregiver and Clinician Reports of Cognitive Difficulties in Patients with Schizophrenia Switching to Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: A Post Hoc Analysis
Discrepancies between patient- and clinician-perceived cognitive functioning in people with schizophrenia have been associated with functional impairment, which can be further confounded by side effects of treatment. Perceived cognitive impairment and level of agreement between patient, clinician, and caregiver responses on the New York Assessment of Adverse Cognitive Effects of Neuropsychiatric Treatment (NY-AACENT) were assessed for patients with schizophrenia switching to the long-acting injectable antipsychotic aripiprazole lauroxil (AL). (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: MGA Opler, A Claxton, J McGrory, SM Gasper, M Wang, S Yagoda Source Type: research

EE232 A Real-World (RW) Comparison of Healthcare Expenditures in Patients Prescribed Aripiprazole Tablet with Sensor (AS) and Patients Prescribed Aripiprazole Alone [Aripiprazole without Sensor (ARI)] in the US
This study compares healthcare expenditures in patients prescribed AS versus a matched ari only cohort. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: D Hadzi Boskovic, M Gorritz, M Yasuda, J He, CC Chen Source Type: research

RWD39 Early Experience with Aripiprazole Tablets with Sensor: Patient Costs from Real-World Data
Aripiprazole tablets with sensor (AS) is an atypical antipsychotic therapy indicated to track medication ingestion behavior. There is a lack of real-world evidence describing the costs associated with healthcare utilization among those prescribed AS. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: D Hadzi Boskovic, E Wiggins, P Parab, JN Liberman Source Type: research

Atypical antipsychotic drugs in dual disorders: current evidence and clinical guidelines
CONCLUSION: The findings highlight the use of SGA for the treatment of psychotic symptoms in comorbidity with substance use. Future studies on people with dual diagnosis and focused on long-term evaluations are warranted and need to investigate the efficacy of newly introduced molecules, such as partial D2 agonists and long-acting injectable antipsychotics.PMID:35747956 | DOI:10.2174/1381612828666220623092853 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - June 24, 2022 Category: Drugs & Pharmacology Authors: Giovanni Martinotti Stefania Chiappini Alessio Mosca Andrea Miuli Maria Chiara Santovito Mauro Pettorruso Valentin Skryabin Stefano L Sensi Massimo Di Giannantonio Source Type: research

Atypical antipsychotic drugs in dual disorders: current evidence and clinical guidelines
CONCLUSION: The findings highlight the use of SGA for the treatment of psychotic symptoms in comorbidity with substance use. Future studies on people with dual diagnosis and focused on long-term evaluations are warranted and need to investigate the efficacy of newly introduced molecules, such as partial D2 agonists and long-acting injectable antipsychotics.PMID:35747956 | DOI:10.2174/1381612828666220623092853 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - June 24, 2022 Category: Drugs & Pharmacology Authors: Giovanni Martinotti Stefania Chiappini Alessio Mosca Andrea Miuli Maria Chiara Santovito Mauro Pettorruso Valentin Skryabin Stefano L Sensi Massimo Di Giannantonio Source Type: research

Atypical antipsychotic drugs in dual disorders: current evidence and clinical guidelines
CONCLUSION: The findings highlight the use of SGA for the treatment of psychotic symptoms in comorbidity with substance use. Future studies on people with dual diagnosis and focused on long-term evaluations are warranted and need to investigate the efficacy of newly introduced molecules, such as partial D2 agonists and long-acting injectable antipsychotics.PMID:35747956 | DOI:10.2174/1381612828666220623092853 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - June 24, 2022 Category: Drugs & Pharmacology Authors: Giovanni Martinotti Stefania Chiappini Alessio Mosca Andrea Miuli Maria Chiara Santovito Mauro Pettorruso Valentin Skryabin Stefano L Sensi Massimo Di Giannantonio Source Type: research

Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020
Turk Psikiyatri Derg. 2022 Summer;33(2):146-148. doi: 10.5080/u26315.ABSTRACTDear Editor, The costs of antipsychotic drugs (APDs) used in the treatment of mental disorders with psychosis are mentioned in treatment guidelines (APA 2021, NICE 2014). While the American Psychiatric Association guideline states that every specialist should make decisions according to the rules and conditions of their country and their region, the National Institute of Health and Clinical Excellence guideline emphasizes that drug costs must be taken into consideration in the treatment process. Classical or first-generation antipsychotic drugs (F...
Source: Turkish Journal of Psychiatry - June 22, 2022 Category: Psychiatry Authors: Mustafa Y ıldız Emre Osman Source Type: research